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115“We are living in unprecedented times.” How many times
have we heard that in the last 3 months? Indeed, it almost
does not register anymore. We are fortunate that few of us
have experienced war in recent times. For those of us who
have, however, the current situation is reminiscent of life
and health care during wartime.
The COVID-19 pandemic has touched every dimension
of our lives: our daily behaviors, our interactions with
family and friends, our leisure time, and, quite dramatically,
our work. As clinicians, the effect on clinical practice has
been possibly the hardest with which to contend. The na-
ture of the adaptations that have become increasingly
necessary, and the scale and speed with which they have
had to be implemented, has truly been unprecedented.
Operating capacity has been slashed as operating rooms
are converted into intensive care space and operating staff
redeployed to man those beds. Ward beds are no longer
available to accommodate routine surgical cases. Those
patients requiring postoperative intensive care can no
longer have their operations. Operative theaters are ra-
tioned, with each case reviewed and approved only by
committee. As a result, we are adapting by doing less
extensive surgery, even if it may mean worse functionalCorresponding author: Hisham Mehanna, PhD, FRCS (ORL); E-mail:
h.mehanna@bham.ac.uk
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https://doi.org/10.1016/j.ijrobp.2020.04.017outcomes, and by accepting delays that we would not
normally countenance. Other patients are recommended
radiation therapy instead of surgery. In some regions, sys-
temic therapy is being considered as a means to delay
surgical procedures.
Medical and radiation oncology services have had to
adapt rapidly, too. Many have experienced increases in
caseload as a result of the reasons noted above. Yet at the
same time, they have had to cope with considerable
reductions in staff owing to COVID-19 infection or
self-isolation. Many services in regions considered hot
spots for COVID-19 have therefore had to reconsider the
standard riskebenefit ratio with which we are normally
comfortable. They have had to consider hypofractionation
radiation therapy regimens to shorten treatment durations,
reduce visits and exposure to hospitals, and increase
patient throughput. In addition, many have weighed the
benefit of concomitant chemotherapy against the signifi-
cant increase in acute toxicity, potential complications and
associated hospital admissions, and the need for more
intensive monitoring. As a result, some have opted for the
omission of concomitant chemotherapy in the curative
setting.Q5
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247As a result of the lack of evidence and literature about
COVID-19, we have had to undertake these decisions with
a high degree of uncertainty. There are many unanswered
questions. Will COVID-19 patients tolerate radiation
therapy in a way similar to non-COVID patients? Is
immunotherapy protective or a risk factor for COVID-19
infection and severity? Does immunosuppression associ-
ated with head and neck cancer and its therapy affect
COVID-19 outcomes? Does COVID-19 infection increase
the risk of complications of surgery? What is the best
tracheostomy technique to reduce aerosol generation? Are
remote follow-up consultations or no consultations at all
safe for patients with head and neck cancer? Who should be
prioritized for treatment in the setting of severe shortages of
capacity? Should a highly curable patient be prioritized
over a palliative patient with symptoms?
As never before, we have become acutely aware (and
appreciative) of the critical role that research has in guiding
our daily practice. Yet we have had to suspend many
research activities. How do we try to maintain ongoing
research, given the necessity of halting clinical trial
enrollment to preserve resources and to comply with
physical distancing? How do we make up for lost oppor-
tunities from the closure of laboratories doing critical
correlative science?
We have been collectively exposed to stresses that we
may have never encountered before. Many of us have had
to care for patients outside our own specialties. Some of us
have had to learn to do venesection or use the stethoscope
again after many decades. And we have all reached out for
the physiology book or the online tutorial on the respiratory
system and blood gases.
We have also learned that some of us, especially in
otorhinolaryngology, dentistry, maxillofacial surgery, and
ophthalmology, appear to be at even higher risk of COVID-
19 infection and occasionally death, presumably due to
high viral loads in the upper airways and regular exposure
to aerosol-generating procedures, such as nasal endoscopy,
dental procedures, tracheostomy, and upper-airway surgery.
Severe curtailment of these procedures has now been
instituted in many centers.
Our physicianepatient relationships are also being
strained. How do we balance the need to provide the best
possible care with restrictions on access to personal
protection equipment, operative theaters, and intensive
care? How do we best balance accurate assessments of
toxicities with travel and exposure risks to our patients
with face-to-face visits? How do we seamlessly transfer
care from major referral centers to local community
oncologists and reassure patients this will not affect
outcomes?
Furthermore, some of us have had to make very difficult
decisions on who will be ventilated and who will not. These
are decisions that we are used to in our normal clinical
practice in oncology, but not at such frequency or scale or
for noncancer indications.EDI 5.6.0 DTD  ROB26301_proofThese are unprecedented psychological stressors. We
need to ensure that working practices allow for downtime
and recovery so that we do not burn out. And like no time
before, we need to be able to support and care for our
fellow clinicians and colleagues. Petty disagreements,
dysfunctional working relationships, and unhelpful
specialty territorial boundaries have no place in these
unprecedented times.
An important way of reducing the stress of uncertainty
and unfamiliarity in clinical practice has been the rapid
development of guidance by different professional bodies.
Their availability has been very welcome to the over-
stretched, overstressed clinicians working on the front line.
However, due to lack of time, resources, and available
evidence, these guidelines are usually developed by local or
national bodies and are based on small group expert
opinion.
In this issue, a new international guideline for the
treatment of patients with head and neck cancer by radia-
tion therapy during the COVID-19 pandemic1 is published.
The authors completed 3 rounds of a Delphi consensus
process that involved 30 radiation oncology experts from
around the world, including China and Southeast Asia, who
have had to deal with the virus the longest. The resulting
guidance, endorsed by the American Society for Radiation
Oncology, the European Society for Radiotherapy and
Oncology, and the Head and Neck Cancer International
Group, makes available the considered consensus advice of
this international group of experts. The approach used by
this guideline has several strengths: the qualitative scientific
methodology, the involvement of experts from across the
globe, and the consideration of 2 different pandemic
scenariosdearly risk mitigation and severely reduced
resources. Remarkably, the whole process was undertaken
in under 2 weeks, a testament to the efforts and commit-
ment of the authors and an example to us all of what can be
achieved.
Additional international efforts are underway. Using the
same methodology, an international consensus guideline is
currently being developed for surgery by the Head and
Neck International Group. Other efforts are underway to
prospectively collect, collate, and rapidly publish data
relevant to decision-making for patients with head and neck
cancer so we can address with data the questions raised
above.
As with all such guidelines, these of course need to be
interpreted and implemented locally; conditions differ from
region to region, country to country, and hospital to hos-
pital. Even in the same hospital, the situation is changing
on a weekly and sometimes daily basis.
But now is the time to rally our extraordinary worldwide
community of head and neck cancer practitioners. Together,
we can get through this crisis with thoughtful guidelines
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